Cargando…

Anti-SARS-CoV-2 spike IgG following injection of the third dose vaccine: A systematic review with meta-analysis of heterologous versus homologous vaccination

BACKGROUND: The mass vaccination is a key strategy to prevent and control the coronavirus disease 2019 (COVID-19) pandemic. Today, several different types of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed worldwide. These vaccines are usually admini...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mojadadi, Mohammad-Shafi, Javadinia, Seyed Alireza, Attarian, Fahimeh, Samami, Elham, Sobhani, Mona
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Public Health
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9878157/ https://www.ncbi.nlm.nih.gov/pubmed/36711369 http://dx.doi.org/10.3389/fpubh.2022.960598

Ejemplares similares

COVID-19 Vaccination in Patients With Malignancy; A Systematic Review and Meta-Analysis of the Efficacy and Safety
por: Javadinia, Seyed Alireza, et al.
Publicado: (2022)

Homologous and Heterologous Covid-19 Booster Vaccinations
por: Atmar, Robert L., et al.
Publicado: (2022)

Anti‐SARS‐CoV‐2 IgG antibody levels among Thai healthcare providers receiving homologous and heterologous COVID‐19 vaccination regimens
por: Kittikraisak, Wanitchaya, et al.
Publicado: (2022)

Anti‐spike IgG antibody kinetics following the second and third doses of BNT162b2 vaccine in nursing home residents
por: Jeulin, Helene, et al.
Publicado: (2022)

Durability of Heterologous and Homologous COVID-19 Vaccine Boosts
por: Tan, C. Sabrina, et al.
Publicado: (2022)

Anti-spike S1 IgA, anti-spike trimeric IgG, and anti-spike RBD IgG response after BNT162b2 COVID-19 mRNA vaccination in healthcare workers
por: Salvagno, Gian Luca, et al.
Publicado: (2021)

The Levels of Anti-SARS-CoV-2 Spike Protein IgG Antibodies Before and After the Third Dose of Vaccination Against COVID-19
por: Łysek-Gładysińska, Małgorzata, et al.
Publicado: (2023)

COVID-19 Vaccination and Cancer, the Need for more Data
por: Javadinia, Seyed Alireza, et al.
Publicado: (2021)

Heterologous Immune Responses of Serum IgG and Secretory IgA Against the Spike Protein of Endemic Coronaviruses During Severe COVID-19
por: Smit, Wouter L., et al.
Publicado: (2022)

The Potential Diagnostic and Prognostic Value of Circulating MicroRNAs in the Assessment of Patients With Prostate Cancer: Rational and Progress
por: Samami, Elham, et al.
Publicado: (2022)

Dynamics of anti-spike IgG antibody after a third BNT162b2 COVID-19 vaccination in Japanese health care workers
por: Ikezaki, Hiroaki, et al.
Publicado: (2022)

SARS-CoV-2 spike RBD-specific IgA and IgG antibodies in breast milk after vaccination with the protein subunit vaccine Abdala
por: Pérez-Bernal, Maylin, et al.
Publicado: (2022)

A Systematic Review and Meta-Analysis on the Number of Adjuvant Temozolomide Cycles in Newly Diagnosed Glioblastoma
por: Attarian, Fahimeh, et al.
Publicado: (2021)

A third vaccine dose equalises the levels of effectiveness and immunogenicity of heterologous or homologous COVID-19 vaccine regimens, Lyon, France, December 2021 to March 2022
por: Guibert, Nicolas, et al.
Publicado: (2023)

Temporal changes in spike IgG levels after two doses of BNT162b2 vaccine in Japanese healthcare workers: Do spike IgG levels at 3 months predict levels 6 or 8 months after vaccination?
por: Takeuchi, Masaaki, et al.
Publicado: (2022)

The efficacy of the prime-boost regimen for heterologous infectious bronchitis vaccines mandates the administration of homologous vaccines
por: Al-Kubati, Anwar A. G., et al.
Publicado: (2022)

Persistence of Anti-SARS-CoV-2 Spike IgG Antibodies Following COVID-19 Vaccines
por: Alharbi, Naif Khalaf, et al.
Publicado: (2022)

Neutralizing and Total/IgG Spike Antibody Responses Following Homologous CoronaVac vs. BNT162b2 Vaccination Up to 90 Days Post-Booster
por: Lau, Chin Shern, et al.
Publicado: (2022)

Broadly Reactive IgG Responses to Heterologous H5 Prime-Boost Influenza Vaccination Are Shaped by Antigenic Relatedness to Priming Strains
por: Wang, Jiong, et al.
Publicado: (2021)

Effect of the third dose of BNT162b2 vaccine on quantitative SARS-CoV-2 spike 1–2 IgG antibody titers in healthcare personnel
por: Romero-Ibarguengoitia, Maria Elena, et al.
Publicado: (2022)

Assessing the immunogenicity and toxicity of the AFPL1-conjugate nicotine vaccine using heterologous and homologous vaccination routes
por: Fraleigh, Nya L., et al.
Publicado: (2019)

Intradermal vaccination of live attenuated influenza vaccine protects mice against homologous and heterologous influenza challenges
por: Lee, Andrew Chak-Yiu, et al.
Publicado: (2021)

Coronavirus Disease 2019-Related Alterations of Total and Anti-Spike IgG Glycosylation in Relation to Age and Anti-Spike IgG Titer
por: Schwedler, Christian, et al.
Publicado: (2022)

HOMOLOGOUS AND HETEROLOGOUS PROTECTION IN MICE VACCINATED WITH THE TWO TYPES OF MOUSE TYPHOID BACILLUS
por: Pritchett, Ida W.
Publicado: (1924)

Neutralizing antibodies induced by homologous and heterologous boosters in CoronaVac vaccines in Chile
por: Acevedo, Johanna, et al.
Publicado: (2023)

Humoral and cellular responses to vaccination with homologous CoronaVac or ChAdOx1 and heterologous third dose with BNT162b2
por: Hayashi, Jackelinne Y., et al.
Publicado: (2022)

Comparison of humoral immunogenicity in solid organ transplant recipients after third-dose mRNA vaccine with homologous or heterologous schedules: An observational study
por: Kang, Ji-Man, et al.
Publicado: (2023)

Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (Covovax(TM)) after homologous and heterologous two-dose regimens
por: Kanokudom, Sitthichai, et al.
Publicado: (2023)

Evaluation of Covid-19 anti-spike IgG antibody five months after the second Covid-19 vaccination
por: Rafie, Reyhaneh Alipoor, et al.
Publicado: (2023)

A Third Dose of mRNA COVID-19 Vaccine Significantly Enhances Anti–SARS-CoV-2 Spike IgG Response in Nursing Home Residents in Italy
por: Fedele, Giorgio, et al.
Publicado: (2022)

Comparison of humoral and cellular immune responses between ChAd-BNT heterologous vaccination and BNT-BNT homologous vaccination following the third BNT dose: A prospective cohort study
por: Sim, Wooho, et al.
Publicado: (2023)

Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial
por: Liu, Xinxue, et al.
Publicado: (2023)

Attenuated recombinant Bordetella pertussis as live vaccines for the protection against homologous and heterologous diseases
por: Locht, C., et al.
Publicado: (1997)

Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil
por: Ranzani, Otavio T., et al.
Publicado: (2022)

Comparing Heterologous and Homologous COVID-19 Vaccination: A Longitudinal Study of Antibody Decay
por: Orlandi, Chiara, et al.
Publicado: (2023)

The Effect of Third Dose of Pfizer/BioNTech and Moderna COVID-19 mRNA Vaccines on IgG Antibody Titers
por: Khuc, Thao A, et al.
Publicado: (2023)

Evaluation of the Anti-Spike (RDB) IgG Titer among Workers Employed at the University of Pisa Vaccinated with Different Types of SARS-CoV-2 Vaccines
por: Foddis, Rudy, et al.
Publicado: (2022)

Passive immunization with polyclonal anti-SHIV IgG: partial protection or increased acquisition of heterologous tier 2 SHIV – depending on IgG dose
por: Sholukh, AM, et al.
Publicado: (2012)

Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose
por: Sholukh, Anton M, et al.
Publicado: (2014)

Human IgG and IgA responses to COVID-19 mRNA vaccines
por: Wisnewski, Adam V., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_iqljiifnptgrl81uu4ah2do29r